Angiex develops TM4SF1-directed antibody-drug conjugate therapies for the treatment of solid cancers.
- Home
- 2026
- 2025
- January Northwest & Rockies Forums
- February Northwest & Rockies Forums
- March Northwest Forums
- April Expo
- April Rockies Forums
- May Northwest & Rockies Forums
- June Keiretsu Forum Denver Investor Summit
- July Northwest & Rockies Forums
- August Expo
- September Northwest & Rockies Forums
- October Northwest & Rockies
- November Northwest & Rockies
- December Best of Keiretsu Forum Investment Showcase
- 2024
- Academy
- Being an Angel Investor
- Blockchain and Crypto
- Building Effective Teams
- Cap Tables
- Cleantech
- Corporate Governance
- Diversity, Equity and Inclusion
- Due Diligence
- Economic Outlook
- Entrepreneurs
- Exits
- Family Office Investing
- Funding Tactics
- Fireside Chat
- Go To Market
- Impact Investing
- Intellectual Property
- Portfolio Diversification
- Risk Management
- Startup Valuation
- Supply Chain
- Tax Academy
- Tech and AI
- Term Sheets
- Due Diligence
- Testimonials
- Training
